Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Needham Maintains Buy on Gamida Cell, Lowers Price Target to $9
Needham analyst Gil Blum maintains Gamida Cell (NASDAQ:GMDA) with a Buy and lowers the price target from $12 to $9.
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers
PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 361 companies set new 52-week lows.
Gamida Cell Priced 12.9M Share Public Offering of Common Stock @$1.55/Share
Gamida Cell Ltd. (Nasdaq: GMDA) announced the pricing of a follow-on public offering of 12,905,000 of its ordinary shares at a public offering price of $1.55 per share for aggregate gross proceeds of $20 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Gamida Cell Announces Launch of Public Offering of Ordinary Shares, Size Not Disclosed
Gamida Cell Ltd. (NASDAQ:GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the launch of a follow-on
Gamida Cell Presents Data Demonstrating The Impact Of Transplantation With Omidubicel For Patients With Hematologic Malignancies At 2022 Cord Blood Connect Meeting
- Patients treated with omidubicel reported higher health-related quality of life scores during first-year post-transplant as compared to transplantation with umbilical cord blood (UCB)
- If approved, Omidubicel is
Recap: Gamida Cell Q2 Earnings
Gamida Cell (NASDAQ:GMDA) reported its Q2 earnings results on Monday, August 15, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell
• Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.